Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000298603 | SCV000463659 | uncertain significance | Combined oxidative phosphorylation deficiency | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000998614 | SCV001154760 | uncertain significance | not provided | 2018-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000998614 | SCV002201019 | uncertain significance | not provided | 2022-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 512 of the AARS2 protein (p.Asp512His). This variant is present in population databases (rs146512155, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with AARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 357070). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000998614 | SCV003918765 | uncertain significance | not provided | 2023-04-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Institute of Human Genetics Munich, |
RCV000578320 | SCV000680132 | likely pathogenic | Combined oxidative phosphorylation defect type 8 | 2017-09-08 | flagged submission | clinical testing |